Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $7.01 USD
Change Today +0.38 / 5.73%
Volume 1.8M
AGEN On Other Exchanges
Symbol
Exchange
NASDAQ CM
As of 8:10 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

agenus inc (AGEN) Snapshot

Open
$6.65
Previous Close
$6.63
Day High
$7.10
Day Low
$6.62
52 Week High
04/28/15 - $8.00
52 Week Low
10/13/14 - $2.56
Market Cap
578.4M
Average Volume 10 Days
1.4M
EPS TTM
$-0.82
Shares Outstanding
82.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for AGENUS INC (AGEN)

agenus inc (AGEN) Related Businessweek News

No Related Businessweek News Found

agenus inc (AGEN) Details

Agenus Inc., an immunotherapy company, engages in discovering and developing innovative treatments for patients with cancer and other diseases. Its treatments focus on providing therapeutic benefit through modulation of immune function. The company offers Retrocyte Display, a platform that screens and generates therapeutic antibody drug candidates focused on advancing checkpoint modulators using a high-throughput approach incorporating human antibody libraries expressed in mammalian B-lymphocytes. It is also developing heat shock protein vaccine, which is in Phase II studies for treating cancer and infectious diseases; and QS-21 Stimulon, a saponin-based vaccine adjuvant for use in pre-clinical and clinical stage vaccine programs that target prophylactic or therapeutic impact in a range of infectious diseases and cancer. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

140 Employees
Last Reported Date: 05/1/15
Founded in 1994

agenus inc (AGEN) Top Compensated Officers

Founder, Executive Chairman, Chief Executive ...
Total Annual Compensation: $502.4K
Principal Financial Officer, Principal Accoun...
Total Annual Compensation: $222.9K
Chief Compliance Officer, Vice President, Gen...
Total Annual Compensation: $289.2K
Chief Business Officer
Total Annual Compensation: $204.3K
Chief Scientific Officer
Total Annual Compensation: $323.8K
Compensation as of Fiscal Year 2014.

agenus inc (AGEN) Key Developments

Agenus Seeks Acquisitions

Agenus Inc. (NasdaqCM:AGEN) is looking for acquisitions. The company has filed a Follow-on Equity Offering and intends to use the net proceeds from this offering to fund our continued research and development initiatives in connection with expanding our product pipeline and for other general corporate purposes, which may include working capital, capital expenditures, and clinical trial expenditures, acquisitions of additional companies or technologies and investments.

Agenus Inc. - Shareholder/Analyst Call

To provide an overview of the company’s proprietary and partnered pipeline, including its antibody platforms and checkpoint modulator programs, its heat shock protein-based vaccine platform and its saponin-based vaccine adjuvant platform and to provide update on its strategic alliances, including those with Incyte and Merck, and its recent strategic acquisition, all within the framework of its overall corporate strategy

Agenus Inc. Announces the Final Results from the Phase 3 Study of Glaxosmithkline’s Malaria Vaccine

Agenus Inc. announced that final results from a large-scale Phase 3 study of GlaxoSmithKline’s malaria vaccine candidate. The study demonstrated a statistically significant reduction against malaria in children who received RTS,S followed by a booster shot of the vaccine at 18 months. RTS,S reduced the number of cases of clinical malaria in young children (aged 5-17 months at first vaccination) by 36%, and in infants (aged 6-12 weeks) by 26% over an average follow-up period of 48 months. This resulted in an average reduction of 1,774 cases of clinical malaria for every 1,000 children vaccinated (aged 5-17 months), and an average reduction of 983 cases of clinical malaria for every 1,000 infants vaccinated over an average 36-month follow-up. Children receiving the vaccine candidate but not a booster dose had lower rates of protection. The study showed that RTS,S averted even more cases of malaria in areas with higher transmission rates. Agenus is eligible for a milestone payment upon approval of RTS,S and royalties from potential commercial sales. QS-21 Stimulon is being evaluated in more than 12 additional vaccine candidates.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AGEN:US $7.01 USD +0.38

AGEN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AGEN.
View Industry Companies
 

Industry Analysis

AGEN

Industry Average

Valuation AGEN Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AGENUS INC, please visit www.agenusbio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.